RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells
Jaafar, Rola Mnich, Katarzyna Dolan, Sarah Hillis, Jennifer Almanza, Aitor Logue, Susan E. Samali, Afshin Gorman, Adrienne M.
Jaafar, Rola
Mnich, Katarzyna
Dolan, Sarah
Hillis, Jennifer
Almanza, Aitor
Logue, Susan E.
Samali, Afshin
Gorman, Adrienne M.
Loading...
Repository DOI
Publication Date
2018-02-06
Type
Article
Downloads
Citation
Jaafar, R., Mnich, K., Dolan, S., Hillis, J., Almanza, A., Logue, S. E.,Samali, A., Gorman, A. M. (2018). RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells. Biochemical and Biophysical Research Communications, 497(1), 115-121. doi: https://doi.org/10.1016/j.bbrc.2018.02.034
Abstract
Receptor-interacting protein 2 (RIP2) is an essential mediator of inflammation and innate immunity, but little is known about its role outside the immune system. Recently, RIP2 has been linked to chemoresistance of triple negative breast cancer (TNBC), the most aggressive breast cancer subtype for which there is an urgent need for targeted therapies. In this study we show that high expression of RIP2 in breast tumors correlates with a worse prognosis and a higher risk of recurrence. We also demonstrate that RIP2 confers TNBC cell resistance against paclitaxel and ceramide-induced apoptosis. Over expression of RIP2 lead to NF-kappa B activation, which contributed to higher expression of pro-survival proteins and cell survival. Conversely, RIP2 knockdown inhibited NF-kappa B signaling, reduced levels of anti-apoptotic proteins and sensitized cells to drug treatment. Together, these data show that RIP2 promotes survival of breast cancer cells through NF-kappa B activation and that targeting RIP2 may be therapeutically beneficial for treatment of TNBC. (C) 2018 Published by Elsevier Inc.
Publisher
Elsevier
Publisher DOI
10.1016/j.bbrc.2018.02.034
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland